Article
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models.
Scientific reports - 18 Mar 2024
La Monica Silvia, Vacondio Federica, Eltayeb Kamal, Lodola Alessio, Volta Francesco, Viglioli Martina, Ferlenghi Francesca, Galvani Francesca, Galetti Maricla, Bonelli Mara, Fumarola Claudia, Cavazzoni Andrea, Flammini Lisa, Verzè Michela, Minari Roberta, Petronini Pier Giorgio, Tiseo Marcello, Mor Marco, Alfieri Roberta
Abstract excerpt
The EGFR tyrosine kinase inhibitor osimertinib has been approved for the first-line treatment of EGFR-mutated Non-Small Cell Lung Cancer (NSCLC) patients. Despite its efficacy, patients develop resistance. Mechanisms of resistance are heterogeneous and not fully understood, and their characterization is essential to find new strategies to overcome resistance. Ceramides are well-known regulators of apoptosis and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.